nodes	percent_of_prediction	percent_of_DWPC	metapath
Captopril—ALB—Vismodegib—skin cancer	0.141	0.288	CbGbCtD
Captopril—ALB—Vemurafenib—skin cancer	0.111	0.227	CbGbCtD
Captopril—ABCB1—Vismodegib—skin cancer	0.0736	0.151	CbGbCtD
Captopril—CYP2D6—Vemurafenib—skin cancer	0.0548	0.112	CbGbCtD
Captopril—ALB—Fluorouracil—skin cancer	0.05	0.102	CbGbCtD
Captopril—ABCB1—Dactinomycin—skin cancer	0.0386	0.0791	CbGbCtD
Captopril—ABCB1—Docetaxel—skin cancer	0.02	0.0408	CbGbCtD
Captopril—REN—forelimb zeugopod—skin cancer	0.0175	0.0734	CbGeAlD
Captopril—MMP2—dermis—skin cancer	0.0124	0.0518	CbGeAlD
Captopril—MMP9—dermis—skin cancer	0.0108	0.045	CbGeAlD
Captopril—REN—arm—skin cancer	0.00757	0.0317	CbGeAlD
Captopril—ACE—forelimb zeugopod—skin cancer	0.00747	0.0313	CbGeAlD
Captopril—MMP2—hindlimb—skin cancer	0.00729	0.0305	CbGeAlD
Captopril—REN—appendage—skin cancer	0.0068	0.0285	CbGeAlD
Captopril—MMP9—hindlimb—skin cancer	0.00634	0.0266	CbGeAlD
Captopril—MMP2—appendage—skin cancer	0.00625	0.0262	CbGeAlD
Captopril—F2—leg—skin cancer	0.0062	0.0259	CbGeAlD
Captopril—F2—forelimb—skin cancer	0.00615	0.0257	CbGeAlD
Captopril—REN—Peptide hormone metabolism—EXOC2—skin cancer	0.00588	0.0805	CbGpPWpGaD
Captopril—F2—hindlimb—skin cancer	0.00553	0.0232	CbGeAlD
Captopril—MMP9—appendage—skin cancer	0.00544	0.0228	CbGeAlD
Captopril—LTA4H—hair follicle—skin cancer	0.00523	0.0219	CbGeAlD
Captopril—MMP2—skin epidermis—skin cancer	0.0052	0.0218	CbGeAlD
Captopril—REN—nerve—skin cancer	0.00482	0.0202	CbGeAlD
Captopril—F2—appendage—skin cancer	0.00475	0.0199	CbGeAlD
Captopril—MMP9—skin epidermis—skin cancer	0.00452	0.0189	CbGeAlD
Captopril—REN—blood vessel—skin cancer	0.00379	0.0159	CbGeAlD
Captopril—MMP2—endothelium—skin cancer	0.00378	0.0158	CbGeAlD
Captopril—ACE—forelimb—skin cancer	0.00376	0.0157	CbGeAlD
Captopril—LTA4H—nipple—skin cancer	0.00355	0.0149	CbGeAlD
Captopril—MMP2—blood vessel—skin cancer	0.00348	0.0146	CbGeAlD
Captopril—ACE—hindlimb—skin cancer	0.00338	0.0142	CbGeAlD
Captopril—MMP9—endothelium—skin cancer	0.00328	0.0137	CbGeAlD
Captopril—ACE—arm—skin cancer	0.00323	0.0135	CbGeAlD
Captopril—MMP9—blood vessel—skin cancer	0.00303	0.0127	CbGeAlD
Captopril—LTA4H—Eicosanoid Synthesis—PTGS2—skin cancer	0.00298	0.0408	CbGpPWpGaD
Captopril—ACE—appendage—skin cancer	0.0029	0.0121	CbGeAlD
Captopril—F2—endothelium—skin cancer	0.00286	0.012	CbGeAlD
Captopril—REN—neck—skin cancer	0.00271	0.0113	CbGeAlD
Captopril—MMP2—FOXM1 transcription factor network—XRCC1—skin cancer	0.0027	0.0369	CbGpPWpGaD
Captopril—F2—blood vessel—skin cancer	0.00264	0.0111	CbGeAlD
Captopril—ACE—Peptide hormone metabolism—EXOC2—skin cancer	0.00263	0.036	CbGpPWpGaD
Captopril—MMP2—Syndecan-2-mediated signaling events—RASA1—skin cancer	0.00253	0.0346	CbGpPWpGaD
Captopril—MMP2—nipple—skin cancer	0.00252	0.0105	CbGeAlD
Captopril—LTA4H—connective tissue—skin cancer	0.00252	0.0105	CbGeAlD
Captopril—MMP2—neck—skin cancer	0.00249	0.0104	CbGeAlD
Captopril—MMP9—neck—skin cancer	0.00217	0.00907	CbGeAlD
Captopril—LTA4H—mammalian vulva—skin cancer	0.00207	0.00868	CbGeAlD
Captopril—ACE—nerve—skin cancer	0.00206	0.00861	CbGeAlD
Captopril—MMP2—Angiopoietin receptor Tie2-mediated signaling—RASA1—skin cancer	0.00194	0.0266	CbGpPWpGaD
Captopril—REN—connective tissue—skin cancer	0.00194	0.00813	CbGeAlD
Captopril—F2—FOXA2 and FOXA3 transcription factor networks—NKX2-1—skin cancer	0.0019	0.026	CbGpPWpGaD
Captopril—F2—neck—skin cancer	0.00189	0.00791	CbGeAlD
Captopril—REN—epithelium—skin cancer	0.00184	0.00772	CbGeAlD
Captopril—LTA4H—lymphoid tissue—skin cancer	0.00184	0.0077	CbGeAlD
Captopril—MMP2—connective tissue—skin cancer	0.00179	0.00747	CbGeAlD
Captopril—LTA4H—female reproductive system—skin cancer	0.00177	0.00743	CbGeAlD
Captopril—ACE—endothelium—skin cancer	0.00175	0.00733	CbGeAlD
Captopril—MMP2—epithelium—skin cancer	0.00169	0.0071	CbGeAlD
Captopril—LTA4H—Arachidonic acid metabolism—PTGS2—skin cancer	0.00166	0.0227	CbGpPWpGaD
Captopril—ACE—blood vessel—skin cancer	0.00161	0.00676	CbGeAlD
Captopril—MMP2—skin of body—skin cancer	0.00161	0.00675	CbGeAlD
Captopril—MMP9—connective tissue—skin cancer	0.00155	0.0065	CbGeAlD
Captopril—MMP2—Regulation of nuclear beta catenin signaling and target gene transcription—MITF—skin cancer	0.0015	0.0205	CbGpPWpGaD
Captopril—LTA4H—head—skin cancer	0.00148	0.00621	CbGeAlD
Captopril—MMP9—epithelium—skin cancer	0.00147	0.00617	CbGeAlD
Captopril—MMP2—mammalian vulva—skin cancer	0.00147	0.00616	CbGeAlD
Captopril—MMP9—skin of body—skin cancer	0.0014	0.00587	CbGeAlD
Captopril—REN—female reproductive system—skin cancer	0.00137	0.00573	CbGeAlD
Captopril—F2—connective tissue—skin cancer	0.00135	0.00567	CbGeAlD
Captopril—MMP2—lymphoid tissue—skin cancer	0.00131	0.00547	CbGeAlD
Captopril—F2—epithelium—skin cancer	0.00129	0.00538	CbGeAlD
Captopril—MMP2—AGE/RAGE pathway—FOXO4—skin cancer	0.00128	0.0175	CbGpPWpGaD
Captopril—MMP2—female reproductive system—skin cancer	0.00126	0.00527	CbGeAlD
Captopril—LTA4H—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	0.00124	0.017	CbGpPWpGaD
Captopril—MMP2—EPH-Ephrin signaling—RASA1—skin cancer	0.00117	0.0161	CbGpPWpGaD
Captopril—ACE—neck—skin cancer	0.00115	0.00483	CbGeAlD
Captopril—REN—head—skin cancer	0.00114	0.00479	CbGeAlD
Captopril—MMP9—lymphoid tissue—skin cancer	0.00114	0.00475	CbGeAlD
Captopril—REN—Metabolism of proteins—EXOC2—skin cancer	0.00111	0.0152	CbGpPWpGaD
Captopril—MMP2—FOXM1 transcription factor network—CDK4—skin cancer	0.0011	0.015	CbGpPWpGaD
Captopril—SLC15A1—epithelium—skin cancer	0.0011	0.00459	CbGeAlD
Captopril—MMP9—female reproductive system—skin cancer	0.00109	0.00458	CbGeAlD
Captopril—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC12A2—skin cancer	0.00106	0.0144	CbGpPWpGaD
Captopril—MMP2—head—skin cancer	0.00105	0.0044	CbGeAlD
Captopril—LTA4H—lymph node—skin cancer	0.00104	0.00435	CbGeAlD
Captopril—MMP9—Endochondral Ossification—PTCH1—skin cancer	0.000999	0.0137	CbGpPWpGaD
Captopril—F2—lymphoid tissue—skin cancer	0.00099	0.00415	CbGeAlD
Captopril—F2—Angiopoietin receptor Tie2-mediated signaling—RASA1—skin cancer	0.000985	0.0135	CbGpPWpGaD
Captopril—MMP9—Regulation of nuclear beta catenin signaling and target gene transcription—MITF—skin cancer	0.000982	0.0135	CbGpPWpGaD
Captopril—F2—female reproductive system—skin cancer	0.000955	0.004	CbGeAlD
Captopril—SLC15A1—mammalian vulva—skin cancer	0.000951	0.00398	CbGeAlD
Captopril—MMP9—Spinal Cord Injury—CSPG4—skin cancer	0.00095	0.013	CbGpPWpGaD
Captopril—MMP2—Validated transcriptional targets of AP1 family members Fra1 and Fra2—CDKN2A—skin cancer	0.000927	0.0127	CbGpPWpGaD
Captopril—MMP9—head—skin cancer	0.000915	0.00383	CbGeAlD
Captopril—MMP2—Direct p53 effectors—MSH2—skin cancer	0.000913	0.0125	CbGpPWpGaD
Captopril—MMP2—FOXM1 transcription factor network—CDKN2A—skin cancer	0.000838	0.0115	CbGpPWpGaD
Captopril—MMP9—AGE/RAGE pathway—FOXO4—skin cancer	0.000838	0.0115	CbGpPWpGaD
Captopril—MMP2—ATF-2 transcription factor network—CDK4—skin cancer	0.000835	0.0114	CbGpPWpGaD
Captopril—ACE—connective tissue—skin cancer	0.000827	0.00347	CbGeAlD
Captopril—MMP2—Direct p53 effectors—MLH1—skin cancer	0.000823	0.0113	CbGpPWpGaD
Captopril—F2—head—skin cancer	0.000798	0.00334	CbGeAlD
Captopril—ACE—epithelium—skin cancer	0.000786	0.00329	CbGeAlD
Captopril—MMP9—EPH-Ephrin signaling—RASA1—skin cancer	0.00077	0.0105	CbGpPWpGaD
Captopril—MMP2—Axon guidance—SCN10A—skin cancer	0.000759	0.0104	CbGpPWpGaD
Captopril—ALB—FOXA2 and FOXA3 transcription factor networks—NKX2-1—skin cancer	0.000754	0.0103	CbGpPWpGaD
Captopril—MMP2—lymph node—skin cancer	0.000736	0.00308	CbGeAlD
Captopril—MMP2—Regulation of nuclear beta catenin signaling and target gene transcription—TERT—skin cancer	0.000731	0.01	CbGpPWpGaD
Captopril—ACE—mammalian vulva—skin cancer	0.000681	0.00285	CbGeAlD
Captopril—MMP9—lymph node—skin cancer	0.000641	0.00268	CbGeAlD
Captopril—Loss of consciousness—Imiquimod—skin cancer	0.000638	0.0032	CcSEcCtD
Captopril—Muscular weakness—Temozolomide—skin cancer	0.000637	0.00319	CcSEcCtD
Captopril—Cough—Imiquimod—skin cancer	0.000633	0.00318	CcSEcCtD
Captopril—Musculoskeletal discomfort—Vemurafenib—skin cancer	0.000633	0.00317	CcSEcCtD
Captopril—Cardiac arrest—Fluorouracil—skin cancer	0.000633	0.00317	CcSEcCtD
Captopril—Ataxia—Fluorouracil—skin cancer	0.000626	0.00314	CcSEcCtD
Captopril—MMP2—Plasma membrane estrogen receptor signaling—NRAS—skin cancer	0.000621	0.00851	CbGpPWpGaD
Captopril—Arthralgia—Imiquimod—skin cancer	0.000618	0.0031	CcSEcCtD
Captopril—Chest pain—Imiquimod—skin cancer	0.000618	0.0031	CcSEcCtD
Captopril—Myalgia—Imiquimod—skin cancer	0.000618	0.0031	CcSEcCtD
Captopril—Discomfort—Imiquimod—skin cancer	0.00061	0.00306	CcSEcCtD
Captopril—Stevens-Johnson syndrome—Dactinomycin—skin cancer	0.00061	0.00306	CcSEcCtD
Captopril—MMP9—Validated transcriptional targets of AP1 family members Fra1 and Fra2—CDKN2A—skin cancer	0.000608	0.00833	CbGpPWpGaD
Captopril—ACE—lymphoid tissue—skin cancer	0.000605	0.00253	CbGeAlD
Captopril—Dry mouth—Imiquimod—skin cancer	0.000604	0.00303	CcSEcCtD
Captopril—Decreased appetite—Vemurafenib—skin cancer	0.000604	0.00303	CcSEcCtD
Captopril—Stomatitis—Dactinomycin—skin cancer	0.0006	0.00301	CcSEcCtD
Captopril—Fatigue—Vemurafenib—skin cancer	0.000599	0.003	CcSEcCtD
Captopril—Constipation—Vemurafenib—skin cancer	0.000594	0.00298	CcSEcCtD
Captopril—Pancytopenia—Temozolomide—skin cancer	0.000593	0.00297	CcSEcCtD
Captopril—Muscular weakness—Fluorouracil—skin cancer	0.000587	0.00294	CcSEcCtD
Captopril—Neutropenia—Temozolomide—skin cancer	0.000584	0.00293	CcSEcCtD
Captopril—ACE—female reproductive system—skin cancer	0.000584	0.00244	CbGeAlD
Captopril—Shock—Imiquimod—skin cancer	0.000583	0.00292	CcSEcCtD
Captopril—Tachycardia—Imiquimod—skin cancer	0.000578	0.0029	CcSEcCtD
Captopril—Pollakiuria—Temozolomide—skin cancer	0.000577	0.00289	CcSEcCtD
Captopril—Erectile dysfunction—Temozolomide—skin cancer	0.000575	0.00288	CcSEcCtD
Captopril—Agranulocytosis—Dactinomycin—skin cancer	0.000574	0.00288	CcSEcCtD
Captopril—Photosensitivity reaction—Temozolomide—skin cancer	0.00057	0.00286	CcSEcCtD
Captopril—Eosinophilia—Fluorouracil—skin cancer	0.000569	0.00286	CcSEcCtD
Captopril—ABCB1—blood vessel—skin cancer	0.000568	0.00238	CbGeAlD
Captopril—Weight decreased—Temozolomide—skin cancer	0.000565	0.00283	CcSEcCtD
Captopril—Anorexia—Imiquimod—skin cancer	0.000565	0.00283	CcSEcCtD
Captopril—Angina pectoris—Fluorouracil—skin cancer	0.00056	0.00281	CcSEcCtD
Captopril—Hepatitis—Dactinomycin—skin cancer	0.000552	0.00277	CcSEcCtD
Captopril—LTA4H—Metabolism—PLIN2—skin cancer	0.000552	0.00756	CbGpPWpGaD
Captopril—Stevens-Johnson syndrome—Temozolomide—skin cancer	0.000552	0.00277	CcSEcCtD
Captopril—MMP2—Metabolism of proteins—EXOC2—skin cancer	0.000552	0.00755	CbGpPWpGaD
Captopril—Flushing—Bleomycin—skin cancer	0.00055	0.00276	CcSEcCtD
Captopril—Body temperature increased—Vemurafenib—skin cancer	0.000549	0.00275	CcSEcCtD
Captopril—Pharyngitis—Dactinomycin—skin cancer	0.000548	0.00275	CcSEcCtD
Captopril—Pancytopenia—Fluorouracil—skin cancer	0.000546	0.00274	CcSEcCtD
Captopril—Stomatitis—Temozolomide—skin cancer	0.000542	0.00272	CcSEcCtD
Captopril—MMP2—Developmental Biology—SCN10A—skin cancer	0.000542	0.00742	CbGpPWpGaD
Captopril—Musculoskeletal discomfort—Imiquimod—skin cancer	0.00054	0.00271	CcSEcCtD
Captopril—Insomnia—Imiquimod—skin cancer	0.000536	0.00269	CcSEcCtD
Captopril—MMP2—Plasma membrane estrogen receptor signaling—KRAS—skin cancer	0.000535	0.00732	CbGpPWpGaD
Captopril—Paraesthesia—Imiquimod—skin cancer	0.000532	0.00267	CcSEcCtD
Captopril—MMP2—amb2 Integrin signaling—IL6—skin cancer	0.000531	0.00727	CbGpPWpGaD
Captopril—Dyspnoea—Imiquimod—skin cancer	0.000528	0.00265	CcSEcCtD
Captopril—Somnolence—Imiquimod—skin cancer	0.000526	0.00264	CcSEcCtD
Captopril—Photosensitivity reaction—Fluorouracil—skin cancer	0.000525	0.00263	CcSEcCtD
Captopril—Alopecia—Bleomycin—skin cancer	0.000523	0.00262	CcSEcCtD
Captopril—Erythema multiforme—Dactinomycin—skin cancer	0.000522	0.00262	CcSEcCtD
Captopril—Dyspepsia—Imiquimod—skin cancer	0.000521	0.00261	CcSEcCtD
Captopril—Decreased appetite—Imiquimod—skin cancer	0.000515	0.00258	CcSEcCtD
Captopril—Flushing—Dactinomycin—skin cancer	0.000513	0.00257	CcSEcCtD
Captopril—Fatigue—Imiquimod—skin cancer	0.000511	0.00256	CcSEcCtD
Captopril—MMP2—Syndecan-2-mediated signaling events—HRAS—skin cancer	0.000504	0.00691	CbGpPWpGaD
Captopril—ABCB1—HIF-1-alpha transcription factor network—PLIN2—skin cancer	0.000504	0.0069	CbGpPWpGaD
Captopril—Dermatitis bullous—Docetaxel—skin cancer	0.000502	0.00252	CcSEcCtD
Captopril—MMP2—Regulation of nuclear beta catenin signaling and target gene transcription—CDKN2A—skin cancer	0.0005	0.00685	CbGpPWpGaD
Captopril—Stomatitis—Fluorouracil—skin cancer	0.0005	0.00251	CcSEcCtD
Captopril—Hepatitis—Temozolomide—skin cancer	0.0005	0.00251	CcSEcCtD
Captopril—Asthenia—Vemurafenib—skin cancer	0.000498	0.0025	CcSEcCtD
Captopril—MMP9—Axon guidance—SCN10A—skin cancer	0.000498	0.00682	CbGpPWpGaD
Captopril—Hallucination—Temozolomide—skin cancer	0.000497	0.00249	CcSEcCtD
Captopril—ACE—Metabolism of proteins—EXOC2—skin cancer	0.000496	0.00679	CbGpPWpGaD
Captopril—Pharyngitis—Temozolomide—skin cancer	0.000496	0.00249	CcSEcCtD
Captopril—Pruritus—Vemurafenib—skin cancer	0.000491	0.00246	CcSEcCtD
Captopril—Alopecia—Dactinomycin—skin cancer	0.000488	0.00245	CcSEcCtD
Captopril—Feeling abnormal—Imiquimod—skin cancer	0.000488	0.00245	CcSEcCtD
Captopril—ACE—head—skin cancer	0.000488	0.00204	CbGeAlD
Captopril—MMP9—Validated targets of C-MYC transcriptional activation—TERT—skin cancer	0.000485	0.00664	CbGpPWpGaD
Captopril—Gastrointestinal pain—Imiquimod—skin cancer	0.000484	0.00243	CcSEcCtD
Captopril—Hyponatraemia—Docetaxel—skin cancer	0.000482	0.00242	CcSEcCtD
Captopril—MMP9—Regulation of nuclear beta catenin signaling and target gene transcription—TERT—skin cancer	0.00048	0.00657	CbGpPWpGaD
Captopril—Agranulocytosis—Fluorouracil—skin cancer	0.000478	0.0024	CcSEcCtD
Captopril—Ill-defined disorder—Bleomycin—skin cancer	0.000478	0.0024	CcSEcCtD
Captopril—F2—Peptide ligand-binding receptors—MC1R—skin cancer	0.000478	0.00655	CbGpPWpGaD
Captopril—Anaemia—Bleomycin—skin cancer	0.000476	0.00239	CcSEcCtD
Captopril—Diarrhoea—Vemurafenib—skin cancer	0.000475	0.00238	CcSEcCtD
Captopril—MMP2—Validated transcriptional targets of AP1 family members Fra1 and Fra2—IL6—skin cancer	0.000472	0.00647	CbGpPWpGaD
Captopril—Erythema multiforme—Temozolomide—skin cancer	0.000472	0.00237	CcSEcCtD
Captopril—SLC15A1—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.000471	0.00646	CbGpPWpGaD
Captopril—Abdominal pain—Imiquimod—skin cancer	0.000468	0.00235	CcSEcCtD
Captopril—Body temperature increased—Imiquimod—skin cancer	0.000468	0.00235	CcSEcCtD
Captopril—Malaise—Bleomycin—skin cancer	0.000465	0.00233	CcSEcCtD
Captopril—Flushing—Temozolomide—skin cancer	0.000464	0.00233	CcSEcCtD
Captopril—Rhinitis—Fluorouracil—skin cancer	0.000461	0.00231	CcSEcCtD
Captopril—Dizziness—Vemurafenib—skin cancer	0.000459	0.0023	CcSEcCtD
Captopril—Pharyngitis—Fluorouracil—skin cancer	0.000457	0.00229	CcSEcCtD
Captopril—MMP9—Signaling by SCF-KIT—FOXO4—skin cancer	0.000456	0.00625	CbGpPWpGaD
Captopril—MMP2—Plasma membrane estrogen receptor signaling—HRAS—skin cancer	0.000455	0.00623	CbGpPWpGaD
Captopril—Ataxia—Docetaxel—skin cancer	0.000452	0.00226	CcSEcCtD
Captopril—Cough—Bleomycin—skin cancer	0.00045	0.00226	CcSEcCtD
Captopril—Ill-defined disorder—Dactinomycin—skin cancer	0.000446	0.00224	CcSEcCtD
Captopril—LTA4H—Metabolism—CSPG4—skin cancer	0.000445	0.00609	CbGpPWpGaD
Captopril—Anaemia—Dactinomycin—skin cancer	0.000444	0.00223	CcSEcCtD
Captopril—Vomiting—Vemurafenib—skin cancer	0.000442	0.00221	CcSEcCtD
Captopril—Alopecia—Temozolomide—skin cancer	0.000441	0.00221	CcSEcCtD
Captopril—Myalgia—Bleomycin—skin cancer	0.000439	0.0022	CcSEcCtD
Captopril—Chest pain—Bleomycin—skin cancer	0.000439	0.0022	CcSEcCtD
Captopril—Orthostatic hypotension—Docetaxel—skin cancer	0.000439	0.0022	CcSEcCtD
Captopril—Rash—Vemurafenib—skin cancer	0.000438	0.0022	CcSEcCtD
Captopril—Dermatitis—Vemurafenib—skin cancer	0.000437	0.00219	CcSEcCtD
Captopril—MMP2—Axon guidance—RASA1—skin cancer	0.000436	0.00597	CbGpPWpGaD
Captopril—Headache—Vemurafenib—skin cancer	0.000435	0.00218	CcSEcCtD
Captopril—MMP9—Validated targets of C-MYC transcriptional activation—CDK4—skin cancer	0.000434	0.00594	CbGpPWpGaD
Captopril—Discomfort—Bleomycin—skin cancer	0.000434	0.00217	CcSEcCtD
Captopril—Malaise—Dactinomycin—skin cancer	0.000434	0.00217	CcSEcCtD
Captopril—Dysgeusia—Temozolomide—skin cancer	0.000426	0.00214	CcSEcCtD
Captopril—Asthenia—Imiquimod—skin cancer	0.000425	0.00213	CcSEcCtD
Captopril—Confusional state—Bleomycin—skin cancer	0.000424	0.00213	CcSEcCtD
Captopril—Anaphylactic shock—Bleomycin—skin cancer	0.000421	0.00211	CcSEcCtD
Captopril—Pruritus—Imiquimod—skin cancer	0.000419	0.0021	CcSEcCtD
Captopril—Nausea—Vemurafenib—skin cancer	0.000412	0.00207	CcSEcCtD
Captopril—Thrombocytopenia—Bleomycin—skin cancer	0.000412	0.00207	CcSEcCtD
Captopril—Vision blurred—Temozolomide—skin cancer	0.00041	0.00206	CcSEcCtD
Captopril—Myalgia—Dactinomycin—skin cancer	0.000409	0.00205	CcSEcCtD
Captopril—Bronchospasm—Docetaxel—skin cancer	0.000408	0.00205	CcSEcCtD
Captopril—MMP9—Plasma membrane estrogen receptor signaling—NRAS—skin cancer	0.000408	0.00558	CbGpPWpGaD
Captopril—Alopecia—Fluorouracil—skin cancer	0.000407	0.00204	CcSEcCtD
Captopril—Diarrhoea—Imiquimod—skin cancer	0.000405	0.00203	CcSEcCtD
Captopril—Discomfort—Dactinomycin—skin cancer	0.000404	0.00203	CcSEcCtD
Captopril—Angina pectoris—Docetaxel—skin cancer	0.000404	0.00203	CcSEcCtD
Captopril—Ill-defined disorder—Temozolomide—skin cancer	0.000403	0.00202	CcSEcCtD
Captopril—Anaemia—Temozolomide—skin cancer	0.000402	0.00202	CcSEcCtD
Captopril—Anorexia—Bleomycin—skin cancer	0.000401	0.00201	CcSEcCtD
Captopril—Angioedema—Temozolomide—skin cancer	0.000397	0.00199	CcSEcCtD
Captopril—Pancytopenia—Docetaxel—skin cancer	0.000394	0.00198	CcSEcCtD
Captopril—Hypotension—Bleomycin—skin cancer	0.000393	0.00197	CcSEcCtD
Captopril—Malaise—Temozolomide—skin cancer	0.000392	0.00197	CcSEcCtD
Captopril—Dizziness—Imiquimod—skin cancer	0.000392	0.00196	CcSEcCtD
Captopril—Neutropenia—Docetaxel—skin cancer	0.000388	0.00195	CcSEcCtD
Captopril—Palpitations—Temozolomide—skin cancer	0.000384	0.00193	CcSEcCtD
Captopril—Thrombocytopenia—Dactinomycin—skin cancer	0.000384	0.00193	CcSEcCtD
Captopril—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000383	0.00192	CcSEcCtD
Captopril—Cough—Temozolomide—skin cancer	0.000379	0.0019	CcSEcCtD
Captopril—Paraesthesia—Bleomycin—skin cancer	0.000378	0.00189	CcSEcCtD
Captopril—Vision blurred—Fluorouracil—skin cancer	0.000378	0.00189	CcSEcCtD
Captopril—Vomiting—Imiquimod—skin cancer	0.000377	0.00189	CcSEcCtD
Captopril—Weight decreased—Docetaxel—skin cancer	0.000375	0.00188	CcSEcCtD
Captopril—Dyspnoea—Bleomycin—skin cancer	0.000375	0.00188	CcSEcCtD
Captopril—Anorexia—Dactinomycin—skin cancer	0.000374	0.00188	CcSEcCtD
Captopril—Rash—Imiquimod—skin cancer	0.000373	0.00187	CcSEcCtD
Captopril—Dermatitis—Imiquimod—skin cancer	0.000373	0.00187	CcSEcCtD
Captopril—Headache—Imiquimod—skin cancer	0.000371	0.00186	CcSEcCtD
Captopril—Anaemia—Fluorouracil—skin cancer	0.00037	0.00186	CcSEcCtD
Captopril—Arthralgia—Temozolomide—skin cancer	0.00037	0.00186	CcSEcCtD
Captopril—Myalgia—Temozolomide—skin cancer	0.00037	0.00186	CcSEcCtD
Captopril—Stevens-Johnson syndrome—Docetaxel—skin cancer	0.000367	0.00184	CcSEcCtD
Captopril—Discomfort—Temozolomide—skin cancer	0.000366	0.00183	CcSEcCtD
Captopril—Decreased appetite—Bleomycin—skin cancer	0.000366	0.00183	CcSEcCtD
Captopril—MMP9—AP-1 transcription factor network—CDKN2A—skin cancer	0.000365	0.005	CbGpPWpGaD
Captopril—Renal failure—Docetaxel—skin cancer	0.000364	0.00182	CcSEcCtD
Captopril—Dry mouth—Temozolomide—skin cancer	0.000362	0.00182	CcSEcCtD
Captopril—Stomatitis—Docetaxel—skin cancer	0.000361	0.00181	CcSEcCtD
Captopril—Jaundice—Docetaxel—skin cancer	0.000361	0.00181	CcSEcCtD
Captopril—Confusional state—Temozolomide—skin cancer	0.000358	0.00179	CcSEcCtD
Captopril—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000358	0.00179	CcSEcCtD
Captopril—ALB—lymph node—skin cancer	0.000357	0.00149	CbGeAlD
Captopril—MMP9—Developmental Biology—SCN10A—skin cancer	0.000355	0.00487	CbGpPWpGaD
Captopril—Anaphylactic shock—Temozolomide—skin cancer	0.000355	0.00178	CcSEcCtD
Captopril—Nausea—Imiquimod—skin cancer	0.000352	0.00176	CcSEcCtD
Captopril—MMP9—Plasma membrane estrogen receptor signaling—KRAS—skin cancer	0.000351	0.0048	CbGpPWpGaD
Captopril—SLC22A6—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.00035	0.00479	CbGpPWpGaD
Captopril—MMP9—amb2 Integrin signaling—IL6—skin cancer	0.000348	0.00477	CbGpPWpGaD
Captopril—Thrombocytopenia—Temozolomide—skin cancer	0.000347	0.00174	CcSEcCtD
Captopril—Feeling abnormal—Bleomycin—skin cancer	0.000347	0.00174	CcSEcCtD
Captopril—Agranulocytosis—Docetaxel—skin cancer	0.000345	0.00173	CcSEcCtD
Captopril—ACE—lymph node—skin cancer	0.000341	0.00143	CbGeAlD
Captopril—Chest pain—Fluorouracil—skin cancer	0.000341	0.00171	CcSEcCtD
Captopril—Myalgia—Fluorouracil—skin cancer	0.000341	0.00171	CcSEcCtD
Captopril—Decreased appetite—Dactinomycin—skin cancer	0.000341	0.00171	CcSEcCtD
Captopril—Fatigue—Dactinomycin—skin cancer	0.000338	0.0017	CcSEcCtD
Captopril—Anorexia—Temozolomide—skin cancer	0.000338	0.0017	CcSEcCtD
Captopril—F2—GPCR ligand binding—PTCH2—skin cancer	0.000338	0.00462	CbGpPWpGaD
Captopril—Discomfort—Fluorouracil—skin cancer	0.000337	0.00169	CcSEcCtD
Captopril—Rhinitis—Docetaxel—skin cancer	0.000333	0.00167	CcSEcCtD
Captopril—Body temperature increased—Bleomycin—skin cancer	0.000333	0.00167	CcSEcCtD
Captopril—Hepatitis—Docetaxel—skin cancer	0.000332	0.00167	CcSEcCtD
Captopril—Confusional state—Fluorouracil—skin cancer	0.00033	0.00165	CcSEcCtD
Captopril—Pharyngitis—Docetaxel—skin cancer	0.00033	0.00165	CcSEcCtD
Captopril—MMP9—Regulation of nuclear beta catenin signaling and target gene transcription—CDKN2A—skin cancer	0.000328	0.00449	CbGpPWpGaD
Captopril—Anaphylactic shock—Fluorouracil—skin cancer	0.000327	0.00164	CcSEcCtD
Captopril—MMP2—ATF-2 transcription factor network—IL6—skin cancer	0.000325	0.00445	CbGpPWpGaD
Captopril—Feeling abnormal—Dactinomycin—skin cancer	0.000323	0.00162	CcSEcCtD
Captopril—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000323	0.00162	CcSEcCtD
Captopril—Insomnia—Temozolomide—skin cancer	0.000321	0.00161	CcSEcCtD
Captopril—Gastrointestinal pain—Dactinomycin—skin cancer	0.000321	0.00161	CcSEcCtD
Captopril—F2—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.000321	0.00439	CbGpPWpGaD
Captopril—Thrombocytopenia—Fluorouracil—skin cancer	0.00032	0.00161	CcSEcCtD
Captopril—Tachycardia—Fluorouracil—skin cancer	0.000319	0.0016	CcSEcCtD
Captopril—Paraesthesia—Temozolomide—skin cancer	0.000319	0.0016	CcSEcCtD
Captopril—MMP2—LPA receptor mediated events—HRAS—skin cancer	0.000318	0.00436	CbGpPWpGaD
Captopril—Dyspnoea—Temozolomide—skin cancer	0.000316	0.00159	CcSEcCtD
Captopril—Somnolence—Temozolomide—skin cancer	0.000316	0.00158	CcSEcCtD
Captopril—MMP9—Spinal Cord Injury—CDK4—skin cancer	0.000315	0.00431	CbGpPWpGaD
Captopril—Erythema multiforme—Docetaxel—skin cancer	0.000314	0.00158	CcSEcCtD
Captopril—Dyspepsia—Temozolomide—skin cancer	0.000312	0.00157	CcSEcCtD
Captopril—Anorexia—Fluorouracil—skin cancer	0.000312	0.00156	CcSEcCtD
Captopril—MMP2—Developmental Biology—RASA1—skin cancer	0.000311	0.00426	CbGpPWpGaD
Captopril—Abdominal pain—Dactinomycin—skin cancer	0.00031	0.00156	CcSEcCtD
Captopril—Body temperature increased—Dactinomycin—skin cancer	0.00031	0.00156	CcSEcCtD
Captopril—MMP9—Validated transcriptional targets of AP1 family members Fra1 and Fra2—IL6—skin cancer	0.00031	0.00424	CbGpPWpGaD
Captopril—Decreased appetite—Temozolomide—skin cancer	0.000309	0.00155	CcSEcCtD
Captopril—Flushing—Docetaxel—skin cancer	0.000308	0.00155	CcSEcCtD
Captopril—Fatigue—Temozolomide—skin cancer	0.000306	0.00153	CcSEcCtD
Captopril—Hypotension—Fluorouracil—skin cancer	0.000306	0.00153	CcSEcCtD
Captopril—Constipation—Temozolomide—skin cancer	0.000303	0.00152	CcSEcCtD
Captopril—LTA4H—Metabolism—ENO2—skin cancer	0.000303	0.00414	CbGpPWpGaD
Captopril—Asthenia—Bleomycin—skin cancer	0.000302	0.00151	CcSEcCtD
Captopril—MMP9—Plasma membrane estrogen receptor signaling—HRAS—skin cancer	0.000298	0.00408	CbGpPWpGaD
Captopril—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000298	0.00149	CcSEcCtD
Captopril—Pruritus—Bleomycin—skin cancer	0.000298	0.00149	CcSEcCtD
Captopril—Insomnia—Fluorouracil—skin cancer	0.000296	0.00148	CcSEcCtD
Captopril—Paraesthesia—Fluorouracil—skin cancer	0.000294	0.00147	CcSEcCtD
Captopril—Alopecia—Docetaxel—skin cancer	0.000294	0.00147	CcSEcCtD
Captopril—Feeling abnormal—Temozolomide—skin cancer	0.000292	0.00147	CcSEcCtD
Captopril—Dyspnoea—Fluorouracil—skin cancer	0.000292	0.00146	CcSEcCtD
Captopril—Somnolence—Fluorouracil—skin cancer	0.000291	0.00146	CcSEcCtD
Captopril—Gastrointestinal pain—Temozolomide—skin cancer	0.00029	0.00146	CcSEcCtD
Captopril—Dyspepsia—Fluorouracil—skin cancer	0.000288	0.00144	CcSEcCtD
Captopril—MMP9—Axon guidance—RASA1—skin cancer	0.000286	0.00392	CbGpPWpGaD
Captopril—CYP2D6—female reproductive system—skin cancer	0.000286	0.0012	CbGeAlD
Captopril—Decreased appetite—Fluorouracil—skin cancer	0.000284	0.00143	CcSEcCtD
Captopril—Dysgeusia—Docetaxel—skin cancer	0.000283	0.00142	CcSEcCtD
Captopril—Asthenia—Dactinomycin—skin cancer	0.000282	0.00141	CcSEcCtD
Captopril—Body temperature increased—Temozolomide—skin cancer	0.000281	0.00141	CcSEcCtD
Captopril—Abdominal pain—Temozolomide—skin cancer	0.000281	0.00141	CcSEcCtD
Captopril—MMP9—TWEAK Signaling Pathway—IL6—skin cancer	0.00028	0.00383	CbGpPWpGaD
Captopril—F2—Metabolism of proteins—EXOC2—skin cancer	0.000279	0.00383	CbGpPWpGaD
Captopril—ABCB1—epithelium—skin cancer	0.000277	0.00116	CbGeAlD
Captopril—MMP9—Signaling Pathways—RHOU—skin cancer	0.000272	0.00372	CbGpPWpGaD
Captopril—Feeling abnormal—Fluorouracil—skin cancer	0.000269	0.00135	CcSEcCtD
Captopril—Diarrhoea—Dactinomycin—skin cancer	0.000268	0.00135	CcSEcCtD
Captopril—Vomiting—Bleomycin—skin cancer	0.000268	0.00134	CcSEcCtD
Captopril—Anaemia—Docetaxel—skin cancer	0.000267	0.00134	CcSEcCtD
Captopril—Rash—Bleomycin—skin cancer	0.000265	0.00133	CcSEcCtD
Captopril—Dermatitis—Bleomycin—skin cancer	0.000265	0.00133	CcSEcCtD
Captopril—Syncope—Docetaxel—skin cancer	0.000259	0.0013	CcSEcCtD
Captopril—Body temperature increased—Fluorouracil—skin cancer	0.000259	0.0013	CcSEcCtD
Captopril—Palpitations—Docetaxel—skin cancer	0.000256	0.00128	CcSEcCtD
Captopril—Asthenia—Temozolomide—skin cancer	0.000255	0.00128	CcSEcCtD
Captopril—Loss of consciousness—Docetaxel—skin cancer	0.000254	0.00127	CcSEcCtD
Captopril—Cough—Docetaxel—skin cancer	0.000252	0.00127	CcSEcCtD
Captopril—Pruritus—Temozolomide—skin cancer	0.000251	0.00126	CcSEcCtD
Captopril—Nausea—Bleomycin—skin cancer	0.00025	0.00125	CcSEcCtD
Captopril—Vomiting—Dactinomycin—skin cancer	0.000249	0.00125	CcSEcCtD
Captopril—Rash—Dactinomycin—skin cancer	0.000247	0.00124	CcSEcCtD
Captopril—Arthralgia—Docetaxel—skin cancer	0.000246	0.00123	CcSEcCtD
Captopril—Myalgia—Docetaxel—skin cancer	0.000246	0.00123	CcSEcCtD
Captopril—Chest pain—Docetaxel—skin cancer	0.000246	0.00123	CcSEcCtD
Captopril—F2—GPCR ligand binding—MC1R—skin cancer	0.000244	0.00334	CbGpPWpGaD
Captopril—Diarrhoea—Temozolomide—skin cancer	0.000243	0.00122	CcSEcCtD
Captopril—Dry mouth—Docetaxel—skin cancer	0.000241	0.00121	CcSEcCtD
Captopril—ABCB1—mammalian vulva—skin cancer	0.00024	0.001	CbGeAlD
Captopril—SLC15A1—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.00024	0.00328	CbGpPWpGaD
Captopril—CYP2D6—head—skin cancer	0.000239	0.000999	CbGeAlD
Captopril—Confusional state—Docetaxel—skin cancer	0.000238	0.00119	CcSEcCtD
Captopril—LTA4H—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	0.000237	0.00324	CbGpPWpGaD
Captopril—Anaphylactic shock—Docetaxel—skin cancer	0.000236	0.00118	CcSEcCtD
Captopril—Dizziness—Temozolomide—skin cancer	0.000235	0.00118	CcSEcCtD
Captopril—MMP2—EPH-Ephrin signaling—HRAS—skin cancer	0.000234	0.00321	CbGpPWpGaD
Captopril—Nausea—Dactinomycin—skin cancer	0.000233	0.00117	CcSEcCtD
Captopril—Shock—Docetaxel—skin cancer	0.000232	0.00116	CcSEcCtD
Captopril—Pruritus—Fluorouracil—skin cancer	0.000231	0.00116	CcSEcCtD
Captopril—Thrombocytopenia—Docetaxel—skin cancer	0.000231	0.00116	CcSEcCtD
Captopril—Tachycardia—Docetaxel—skin cancer	0.00023	0.00116	CcSEcCtD
Captopril—Vomiting—Temozolomide—skin cancer	0.000226	0.00113	CcSEcCtD
Captopril—Anorexia—Docetaxel—skin cancer	0.000225	0.00113	CcSEcCtD
Captopril—MMP9—Spinal Cord Injury—PTGS2—skin cancer	0.000225	0.00308	CbGpPWpGaD
Captopril—Rash—Temozolomide—skin cancer	0.000224	0.00112	CcSEcCtD
Captopril—Diarrhoea—Fluorouracil—skin cancer	0.000224	0.00112	CcSEcCtD
Captopril—Dermatitis—Temozolomide—skin cancer	0.000224	0.00112	CcSEcCtD
Captopril—Headache—Temozolomide—skin cancer	0.000222	0.00112	CcSEcCtD
Captopril—Hypotension—Docetaxel—skin cancer	0.000221	0.00111	CcSEcCtD
Captopril—F2—Selenium Micronutrient Network—PTGS2—skin cancer	0.00022	0.00301	CbGpPWpGaD
Captopril—Dizziness—Fluorouracil—skin cancer	0.000216	0.00108	CcSEcCtD
Captopril—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000215	0.00108	CcSEcCtD
Captopril—Insomnia—Docetaxel—skin cancer	0.000213	0.00107	CcSEcCtD
Captopril—ABCB1—lymphoid tissue—skin cancer	0.000213	0.000892	CbGeAlD
Captopril—Paraesthesia—Docetaxel—skin cancer	0.000212	0.00106	CcSEcCtD
Captopril—F2—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.000211	0.00289	CbGpPWpGaD
Captopril—Nausea—Temozolomide—skin cancer	0.000211	0.00106	CcSEcCtD
Captopril—Dyspnoea—Docetaxel—skin cancer	0.00021	0.00106	CcSEcCtD
Captopril—Somnolence—Docetaxel—skin cancer	0.00021	0.00105	CcSEcCtD
Captopril—F2—Signaling Pathways—RHOU—skin cancer	0.00021	0.00287	CbGpPWpGaD
Captopril—MMP9—LPA receptor mediated events—HRAS—skin cancer	0.000209	0.00286	CbGpPWpGaD
Captopril—Vomiting—Fluorouracil—skin cancer	0.000208	0.00104	CcSEcCtD
Captopril—Dyspepsia—Docetaxel—skin cancer	0.000208	0.00104	CcSEcCtD
Captopril—Rash—Fluorouracil—skin cancer	0.000206	0.00103	CcSEcCtD
Captopril—Dermatitis—Fluorouracil—skin cancer	0.000206	0.00103	CcSEcCtD
Captopril—ABCB1—female reproductive system—skin cancer	0.000205	0.00086	CbGeAlD
Captopril—Decreased appetite—Docetaxel—skin cancer	0.000205	0.00103	CcSEcCtD
Captopril—Headache—Fluorouracil—skin cancer	0.000205	0.00103	CcSEcCtD
Captopril—MMP9—Developmental Biology—RASA1—skin cancer	0.000204	0.00279	CbGpPWpGaD
Captopril—Fatigue—Docetaxel—skin cancer	0.000203	0.00102	CcSEcCtD
Captopril—MMP9—AP-1 transcription factor network—TP53—skin cancer	0.000203	0.00278	CbGpPWpGaD
Captopril—Constipation—Docetaxel—skin cancer	0.000202	0.00101	CcSEcCtD
Captopril—Feeling abnormal—Docetaxel—skin cancer	0.000194	0.000975	CcSEcCtD
Captopril—Nausea—Fluorouracil—skin cancer	0.000194	0.000974	CcSEcCtD
Captopril—Gastrointestinal pain—Docetaxel—skin cancer	0.000193	0.000968	CcSEcCtD
Captopril—Body temperature increased—Docetaxel—skin cancer	0.000187	0.000936	CcSEcCtD
Captopril—Abdominal pain—Docetaxel—skin cancer	0.000187	0.000936	CcSEcCtD
Captopril—MMP9—AP-1 transcription factor network—IL6—skin cancer	0.000186	0.00255	CbGpPWpGaD
Captopril—F2—Vitamin B12 Metabolism—IL6—skin cancer	0.000185	0.00253	CbGpPWpGaD
Captopril—MMP9—Validated targets of C-MYC transcriptional activation—TP53—skin cancer	0.000185	0.00253	CbGpPWpGaD
Captopril—ALB—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.000182	0.00249	CbGpPWpGaD
Captopril—F2—Regulation of Actin Cytoskeleton—BRAF—skin cancer	0.000178	0.00244	CbGpPWpGaD
Captopril—MMP2—Direct p53 effectors—TP53—skin cancer	0.000178	0.00244	CbGpPWpGaD
Captopril—SLC22A6—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.000178	0.00244	CbGpPWpGaD
Captopril—LTA4H—Metabolism—ERCC2—skin cancer	0.000176	0.00241	CbGpPWpGaD
Captopril—F2—GPCR ligand binding—SHH—skin cancer	0.000174	0.00238	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—PTCH2—skin cancer	0.000173	0.00237	CbGpPWpGaD
Captopril—ABCB1—head—skin cancer	0.000172	0.000719	CbGeAlD
Captopril—Asthenia—Docetaxel—skin cancer	0.000169	0.000849	CcSEcCtD
Captopril—Pruritus—Docetaxel—skin cancer	0.000167	0.000837	CcSEcCtD
Captopril—F2—GPCR ligand binding—SMO—skin cancer	0.000165	0.00226	CbGpPWpGaD
Captopril—F2—GPCR ligand binding—PTCH1—skin cancer	0.000165	0.00226	CbGpPWpGaD
Captopril—F2—Folate Metabolism—TP53—skin cancer	0.000165	0.00225	CbGpPWpGaD
Captopril—Diarrhoea—Docetaxel—skin cancer	0.000161	0.00081	CcSEcCtD
Captopril—F2—GPCR ligand binding—PTGER4—skin cancer	0.000161	0.0022	CbGpPWpGaD
Captopril—Dizziness—Docetaxel—skin cancer	0.000156	0.000783	CcSEcCtD
Captopril—F2—Cell surface interactions at the vascular wall—NRAS—skin cancer	0.000155	0.00213	CbGpPWpGaD
Captopril—MMP9—EPH-Ephrin signaling—HRAS—skin cancer	0.000154	0.0021	CbGpPWpGaD
Captopril—MMP2—Developmental Biology—CDK4—skin cancer	0.000153	0.00209	CbGpPWpGaD
Captopril—MMP9—Signaling by SCF-KIT—NRAS—skin cancer	0.000152	0.00208	CbGpPWpGaD
Captopril—F2—Folate Metabolism—IL6—skin cancer	0.000151	0.00206	CbGpPWpGaD
Captopril—ABCB1—HIF-1-alpha transcription factor network—TERT—skin cancer	0.00015	0.00206	CbGpPWpGaD
Captopril—Vomiting—Docetaxel—skin cancer	0.00015	0.000753	CcSEcCtD
Captopril—Rash—Docetaxel—skin cancer	0.000149	0.000746	CcSEcCtD
Captopril—Dermatitis—Docetaxel—skin cancer	0.000149	0.000746	CcSEcCtD
Captopril—Headache—Docetaxel—skin cancer	0.000148	0.000742	CcSEcCtD
Captopril—Nausea—Docetaxel—skin cancer	0.00014	0.000703	CcSEcCtD
Captopril—F2—GPCR downstream signaling—MC1R—skin cancer	0.000138	0.00189	CbGpPWpGaD
Captopril—MMP9—Spinal Cord Injury—TP53—skin cancer	0.000134	0.00183	CbGpPWpGaD
Captopril—F2—Cell surface interactions at the vascular wall—KRAS—skin cancer	0.000134	0.00183	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—PTCH2—skin cancer	0.000133	0.00182	CbGpPWpGaD
Captopril—MMP9—Signaling by SCF-KIT—KRAS—skin cancer	0.000131	0.00179	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—MC1R—skin cancer	0.000125	0.00172	CbGpPWpGaD
Captopril—MMP9—Spinal Cord Injury—IL6—skin cancer	0.000123	0.00168	CbGpPWpGaD
Captopril—ABCB1—lymph node—skin cancer	0.00012	0.000503	CbGeAlD
Captopril—F2—Selenium Micronutrient Network—IL6—skin cancer	0.00012	0.00164	CbGpPWpGaD
Captopril—MMP2—Axon guidance—NRAS—skin cancer	0.000119	0.00163	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—SHH—skin cancer	0.000118	0.00161	CbGpPWpGaD
Captopril—F2—Cell surface interactions at the vascular wall—HRAS—skin cancer	0.000114	0.00156	CbGpPWpGaD
Captopril—F2—Regulation of Actin Cytoskeleton—NRAS—skin cancer	0.000112	0.00154	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—skin cancer	0.000112	0.00153	CbGpPWpGaD
Captopril—MMP9—Signaling by SCF-KIT—HRAS—skin cancer	0.000111	0.00152	CbGpPWpGaD
Captopril—MMP9—Signaling by SCF-KIT—IL6—skin cancer	0.000106	0.00146	CbGpPWpGaD
Captopril—LTA4H—Metabolism—PTGS2—skin cancer	0.000105	0.00144	CbGpPWpGaD
Captopril—ALB—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	0.000103	0.0014	CbGpPWpGaD
Captopril—F2—Signaling Pathways—PTCH2—skin cancer	0.000102	0.0014	CbGpPWpGaD
Captopril—MMP2—Axon guidance—KRAS—skin cancer	0.000102	0.0014	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—GLI2—skin cancer	0.0001	0.00138	CbGpPWpGaD
Captopril—MMP9—Developmental Biology—CDK4—skin cancer	0.0001	0.00137	CbGpPWpGaD
Captopril—F2—Regulation of Actin Cytoskeleton—KRAS—skin cancer	9.65e-05	0.00132	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—MC1R—skin cancer	9.59e-05	0.00131	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—GLI1—skin cancer	9.45e-05	0.00129	CbGpPWpGaD
Captopril—ALB—Transmembrane transport of small molecules—SLC12A2—skin cancer	9.24e-05	0.00127	CbGpPWpGaD
Captopril—F2—GPCR downstream signaling—PTGER4—skin cancer	9.07e-05	0.00124	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—SUFU—skin cancer	8.96e-05	0.00123	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—SHH—skin cancer	8.93e-05	0.00122	CbGpPWpGaD
Captopril—ALB—Selenium Micronutrient Network—PTGS2—skin cancer	8.71e-05	0.00119	CbGpPWpGaD
Captopril—MMP2—Axon guidance—HRAS—skin cancer	8.7e-05	0.00119	CbGpPWpGaD
Captopril—MMP2—Developmental Biology—NRAS—skin cancer	8.48e-05	0.00116	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—PTCH1—skin cancer	8.46e-05	0.00116	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—SMO—skin cancer	8.46e-05	0.00116	CbGpPWpGaD
Captopril—F2—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	8.36e-05	0.00114	CbGpPWpGaD
Captopril—MMP2—Axon guidance—IL6—skin cancer	8.33e-05	0.00114	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—PTGER4—skin cancer	8.24e-05	0.00113	CbGpPWpGaD
Captopril—ABCB1—Transmembrane transport of small molecules—SLC12A2—skin cancer	8.1e-05	0.00111	CbGpPWpGaD
Captopril—MMP9—Axon guidance—NRAS—skin cancer	7.8e-05	0.00107	CbGpPWpGaD
Captopril—F2—Signaling Pathways—GLI2—skin cancer	7.76e-05	0.00106	CbGpPWpGaD
Captopril—F2—Signaling Pathways—MC1R—skin cancer	7.4e-05	0.00101	CbGpPWpGaD
Captopril—ALB—Vitamin B12 Metabolism—IL6—skin cancer	7.34e-05	0.00101	CbGpPWpGaD
Captopril—MMP2—Developmental Biology—KRAS—skin cancer	7.3e-05	0.001	CbGpPWpGaD
Captopril—F2—Signaling Pathways—GLI1—skin cancer	7.29e-05	0.000999	CbGpPWpGaD
Captopril—F2—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	7.2e-05	0.000985	CbGpPWpGaD
Captopril—F2—Signaling Pathways—SUFU—skin cancer	6.91e-05	0.000947	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—SHH—skin cancer	6.83e-05	0.000935	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—RASA1—skin cancer	6.79e-05	0.000929	CbGpPWpGaD
Captopril—MMP9—Axon guidance—KRAS—skin cancer	6.71e-05	0.000919	CbGpPWpGaD
Captopril—ALB—Folate Metabolism—TP53—skin cancer	6.53e-05	0.000894	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—PTCH1—skin cancer	6.48e-05	0.000887	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—SMO—skin cancer	6.48e-05	0.000887	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—PTGER4—skin cancer	6.3e-05	0.000863	CbGpPWpGaD
Captopril—MMP2—Developmental Biology—HRAS—skin cancer	6.21e-05	0.00085	CbGpPWpGaD
Captopril—F2—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	6.12e-05	0.000838	CbGpPWpGaD
Captopril—ALB—Folate Metabolism—IL6—skin cancer	5.97e-05	0.000818	CbGpPWpGaD
Captopril—MMP2—Developmental Biology—IL6—skin cancer	5.94e-05	0.000814	CbGpPWpGaD
Captopril—F2—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	5.85e-05	0.000802	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	5.75e-05	0.000787	CbGpPWpGaD
Captopril—MMP9—Axon guidance—HRAS—skin cancer	5.71e-05	0.000781	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—FOXO4—skin cancer	5.57e-05	0.000762	CbGpPWpGaD
Captopril—MMP9—Developmental Biology—NRAS—skin cancer	5.57e-05	0.000762	CbGpPWpGaD
Captopril—MMP9—Axon guidance—IL6—skin cancer	5.46e-05	0.000748	CbGpPWpGaD
Captopril—F2—Signaling Pathways—SHH—skin cancer	5.27e-05	0.000722	CbGpPWpGaD
Captopril—F2—Signaling Pathways—RASA1—skin cancer	5.24e-05	0.000718	CbGpPWpGaD
Captopril—F2—Signaling Pathways—PTCH1—skin cancer	5e-05	0.000685	CbGpPWpGaD
Captopril—F2—Signaling Pathways—SMO—skin cancer	5e-05	0.000685	CbGpPWpGaD
Captopril—F2—Signaling Pathways—PTGER4—skin cancer	4.87e-05	0.000666	CbGpPWpGaD
Captopril—MMP9—Developmental Biology—KRAS—skin cancer	4.79e-05	0.000656	CbGpPWpGaD
Captopril—ALB—Selenium Micronutrient Network—IL6—skin cancer	4.75e-05	0.00065	CbGpPWpGaD
Captopril—ALB—Metabolism—PLIN2—skin cancer	4.57e-05	0.000625	CbGpPWpGaD
Captopril—F2—Signaling Pathways—FOXO4—skin cancer	4.3e-05	0.000589	CbGpPWpGaD
Captopril—F2—Hemostasis—NRAS—skin cancer	4.22e-05	0.000577	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	4.11e-05	0.000562	CbGpPWpGaD
Captopril—MMP9—Developmental Biology—HRAS—skin cancer	4.07e-05	0.000558	CbGpPWpGaD
Captopril—ABCB1—Metabolism—PLIN2—skin cancer	4e-05	0.000548	CbGpPWpGaD
Captopril—MMP9—Developmental Biology—IL6—skin cancer	3.9e-05	0.000534	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—PLIN2—skin cancer	3.77e-05	0.000516	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—TERT—skin cancer	3.72e-05	0.000509	CbGpPWpGaD
Captopril—ALB—Metabolism—CSPG4—skin cancer	3.68e-05	0.000504	CbGpPWpGaD
Captopril—F2—Hemostasis—KRAS—skin cancer	3.63e-05	0.000497	CbGpPWpGaD
Captopril—ABCB1—Metabolism—CSPG4—skin cancer	3.23e-05	0.000442	CbGpPWpGaD
Captopril—F2—Hemostasis—TP53—skin cancer	3.22e-05	0.000442	CbGpPWpGaD
Captopril—F2—Hemostasis—HRAS—skin cancer	3.08e-05	0.000422	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—CSPG4—skin cancer	3.04e-05	0.000416	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—BRAF—skin cancer	2.95e-05	0.000403	CbGpPWpGaD
Captopril—F2—Signaling Pathways—TERT—skin cancer	2.87e-05	0.000393	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	2.75e-05	0.000377	CbGpPWpGaD
Captopril—ALB—Metabolism—ENO2—skin cancer	2.5e-05	0.000343	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	2.44e-05	0.000335	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—NRAS—skin cancer	2.42e-05	0.000331	CbGpPWpGaD
Captopril—F2—Signaling Pathways—BRAF—skin cancer	2.27e-05	0.000311	CbGpPWpGaD
Captopril—ABCB1—Metabolism—ENO2—skin cancer	2.19e-05	0.0003	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—KRAS—skin cancer	2.08e-05	0.000285	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—ENO2—skin cancer	2.07e-05	0.000283	CbGpPWpGaD
Captopril—ALB—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.96e-05	0.000268	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—NRAS—skin cancer	1.85e-05	0.000253	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—HRAS—skin cancer	1.77e-05	0.000242	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—IL6—skin cancer	1.69e-05	0.000232	CbGpPWpGaD
Captopril—ALB—Hemostasis—NRAS—skin cancer	1.67e-05	0.000229	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—KRAS—skin cancer	1.59e-05	0.000218	CbGpPWpGaD
Captopril—ALB—Metabolism—ERCC2—skin cancer	1.45e-05	0.000199	CbGpPWpGaD
Captopril—ALB—Hemostasis—KRAS—skin cancer	1.44e-05	0.000197	CbGpPWpGaD
Captopril—F2—Signaling Pathways—NRAS—skin cancer	1.43e-05	0.000196	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—TP53—skin cancer	1.42e-05	0.000194	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—HRAS—skin cancer	1.35e-05	0.000185	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—IL6—skin cancer	1.3e-05	0.000177	CbGpPWpGaD
Captopril—ALB—Hemostasis—TP53—skin cancer	1.28e-05	0.000175	CbGpPWpGaD
Captopril—ABCB1—Metabolism—ERCC2—skin cancer	1.27e-05	0.000174	CbGpPWpGaD
Captopril—F2—Signaling Pathways—KRAS—skin cancer	1.23e-05	0.000168	CbGpPWpGaD
Captopril—ALB—Hemostasis—HRAS—skin cancer	1.22e-05	0.000168	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—ERCC2—skin cancer	1.2e-05	0.000164	CbGpPWpGaD
Captopril—F2—Signaling Pathways—TP53—skin cancer	1.09e-05	0.00015	CbGpPWpGaD
Captopril—F2—Signaling Pathways—HRAS—skin cancer	1.05e-05	0.000143	CbGpPWpGaD
Captopril—F2—Signaling Pathways—IL6—skin cancer	1e-05	0.000137	CbGpPWpGaD
Captopril—ALB—Metabolism—PTGS2—skin cancer	8.72e-06	0.000119	CbGpPWpGaD
Captopril—ABCB1—Metabolism—PTGS2—skin cancer	7.64e-06	0.000105	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—PTGS2—skin cancer	7.2e-06	9.85e-05	CbGpPWpGaD
